Gufic BioSciences Ltd's Q3FY25 Quarter Results
- 15 Feb 2025
Result Summary
- Gufic BioSciences Ltd reported a 2.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 3.7%.
- Its expenses for the quarter were up by 4.8% QoQ and 6.2% YoY.
- The net profit decreased 11.3% QoQ and decreased 13.3% YoY.
- The earnings per share (EPS) of Gufic BioSciences Ltd stood at 1.9 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 209.66 | 204.29 | 202.20 | 2.6% | 3.7% |
Total Expenses | 183.40 | 175.04 | 172.64 | 4.8% | 6.2% |
Profit Before Tax | 26.26 | 29.25 | 29.56 | -10.2% | -11.2% |
Tax | 6.96 | 7.49 | 7.30 | -7.1% | -4.7% |
Profit After Tax | 19.31 | 21.77 | 22.26 | -11.3% | -13.3% |
Earnings Per Share | 1.90 | 2.20 | 2.20 | -13.6% | -13.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Gufic BioSciences Ltd is a prominent company operating within the pharmaceutical and healthcare industry. The company is known for its production and distribution of a wide range of pharmaceutical products, including formulations, APIs, and herbal products. Gufic BioSciences has been engaged in the development and manufacture of healthcare solutions that cater to various medical needs. As of the latest updates, the company has not reported any major recent developments or strategic changes in its business operations.
Revenue
During the third quarter of the fiscal year 2025 (Q3FY25), Gufic BioSciences Ltd reported a total income of ₹209.66 crores, which represents a quarter-over-quarter (QoQ) increase of 2.6% from ₹204.29 crores in the second quarter of the same fiscal year (Q2FY25). Additionally, there was a year-over-year (YoY) growth of 3.7% compared to the third quarter of the previous fiscal year (Q3FY24), where the total income was ₹202.20 crores. This data reflects a steady rise in the company's revenue generation over both the immediate past quarter and the same quarter of the previous year.
Profitability
In Q3FY25, Gufic BioSciences Ltd recorded a profit before tax of ₹26.26 crores. This figure marks a notable decrease of 10.2% QoQ from ₹29.25 crores in Q2FY25 and an 11.2% decline YoY from ₹29.56 crores in Q3FY24. The profit after tax also followed a similar pattern, standing at ₹19.31 crores in Q3FY25, which is down by 11.3% QoQ from ₹21.77 crores and by 13.3% YoY from ₹22.26 crores. These reductions in profitability metrics are further reflected in the earnings per share, which decreased by 13.6% both QoQ and YoY, from ₹2.20 in the previous periods to ₹1.90 in the current quarter.
Operating Metrics
The total expenses for Gufic BioSciences Ltd in Q3FY25 amounted to ₹183.40 crores, representing an increase of 4.8% QoQ from ₹175.04 crores in Q2FY25 and a 6.2% rise YoY from ₹172.64 crores in Q3FY24. A tax expense of ₹6.96 crores was recorded for Q3FY25, which shows a decrease of 7.1% QoQ from ₹7.49 crores and a 4.7% reduction YoY from ₹7.30 crores. These metrics indicate a growth in operational expenses over the evaluated periods, despite a reduction in tax outlays. The company's earnings per share (EPS) were ₹1.90 in Q3FY25, reflecting a 13.6% decline both QoQ and YoY from ₹2.20, indicating changes in operational efficiency and financial distribution strategies over time.
